Alberta committee suggests free HPV vaccine for boys

Mon, May 7, 2012

0 Comments

Source: CBC News

Cost to the province estimated between $5 million and $8 million

The province is considering offering boys free immunizations against the human papillomavirus.

The HPV vaccination is currently offered on a voluntary basis to all girls in Alberta entering Grade 5. The vaccine is said to prevent 70 per cent of cervical cancers, according to Alberta Health and Wellness.

Two strains of HPV are also thought to be a cause of anal, penile and oral cancers.

Susan Morgan’s husband was diagnosed with Stage 4 oral cancer, which they later found out was caused by the HPV virus.

She has been lobbying to have the vaccine for boys covered by the province and was astounded the HPV vaccination was only free for girls.

Morgan says the effects of the radiation and chemotherapy treatment for the cancer were horrific.

“You have open sores in your mouth,” she said. “You start to lose your ability to swallow; you end up on a feeding tube.”

Free vaccine for boys recommended

A report by an advisory committee in Alberta recommends extending HPV coverage to boys.

Chief medical officer Dr. Andre Corriveau says that would cost between $5 million and $8 million.

Now he’ll review the report and advise the province by the end of the month.

“I have a responsibility right now to make sure our system has the capacity to deliver,” he said.

But, for the Morgans, waiting is not an option and they have decided to pay hundreds of dollars to vaccinate both of their sons.

A HPV vaccination for boys has been endorsed by the federal government.

This news story was resourced by the Oral Cancer Foundation, and vetted for appropriateness and accuracy.

Print Friendly
Spread The Word:
  • Digg
  • del.icio.us
  • Facebook
  • Google Bookmarks
  • email
  • Furl
  • MySpace
  • TwitThis
Continue reading...

Photographer inspires others with throat cancer survival

Mon, May 7, 2012

0 Comments

Source: www.getsurrey.co.uk
Author: Rebecca Younger

When Thames Ditton photographer, Keith Hern, was diagnosed with throat cancer five years ago, he dealt with it the only way he knew how – by taking pictures.

Through an incredibly honest and stark photographic portrayal of his treatment, Keith captured everything from the first bout of chemotherapy at the Royal Marsden Hospital in London to the making of his radiotherapy mask and the eight-inch scar left on his neck after an operation to remove dead cancer cells. The candid imagery appears in Keith’s book, Bangers & Mash, which he started writing shortly after he was first diagnosed in 2007.

“I’d started writing a couple of days after diagnosis as the only way I could maintain some semblance of mental control, it would later become therapeutic,” he recounted. “My treatment consisted of five days of 24×7 chemotherapy, 11 days off, five days of chemotherapy again, 11 days off, then radiotherapy for six weeks daily with two top-up chemo sessions in weeks one and five.

“Radiotherapy side effects kicked in at the end of week one – I could no longer eat, then lost my taste, then I couldn’t sleep (my mouth was so dry I was sipping water 24×7), I lost two-and-a-half stone in the six weeks.”

Keith worked with a Neurolinguistic Programming (NLP) coach to stay positive and it was while talking to her about writing a book of his experiences that the idea for a photo diary came about.

“She laughed at the idea and said, why didn’t I do what I was good at and photograph the treatment. It really started there,” he said.

Bangers & Mash, so titled because that was the first proper meal Keith ate after coming through the disease (treatment meant eating solids was painful and food in general tasteless), was published in November 2009. The book not only recorded Keith’s experiences at the Royal Marsden but also his fundraising expeditions to raise cash for hospital including a trek in Iceland, which raised around £7,000.

“That was a real achievement for me. When I first saw the leaflet for the trek at the hospital in 2007, I was at my lowest ebb. I signed up not knowing if I would be alive a year later to actually take part,” the 54-year-old said.

Quite ironically, just two weeks after Keith saw his incredible story of survival in print, he was told the cancer had returned, this time in his chest.

“I was given a 10% to 40% chance of survival. The tumour was too inaccessible and close to key organs to operate so I had to have three sets of five-day chemotherapy sessions, followed by four weeks of daily radiotherapy,” he explained. “That’s a pretty sobering fact to be told, but having survived before I was determined to do so again.

“A lot of it is in the mind. I know three people who were given three months to live – for one of them that was 25 years ago and they are still here.”

In May 2010, Keith was once again pronounced clear of the cancer and it was around this time that publicity surrounding his book began to grow, partly due to Hollywood actor Michael Douglas’ high profile diagnosis later that year.

“I was then interviewed on radio, in the Daily Mail, and then on ITV’s This Morning, from which a number of people got in touch including one young lady recently diagnosed and in the same mental state as I was at the start,” he said. “She found Bangers & Mash really helpful and gave a great testimonial.”

Keith has started a follow-up book and regularly gives motivational talks to businesses, schools and groups across Surrey. He is also planning another fundraising expedition to Nepal in November to raise more money for the Marsden.

“I’d like to think my story not only helps those living with throat cancer but also their relatives and even those, who have had no experience of the disease,” Keith said. “Talking about it and being completely open about the whole experience, warts and all, raises awareness and that can only be a good thing.”

Print Friendly
Spread The Word:
  • Digg
  • del.icio.us
  • Facebook
  • Google Bookmarks
  • email
  • Furl
  • MySpace
  • TwitThis
Continue reading...

New method of predicting the spread of throat cancer to other body parts found

Mon, May 7, 2012

0 Comments

Source: starglobaltribune.com
Author: staff

Independent of other factors, such as smoking history and HPV status, matted lymph nodes appear to signal increased chance of oropharyngeal cancer spreading to other parts of the body.

Researchers at the University of Michigan Health System have found a new indicator that may predict which patients with a common type of throat cancer are most likely have the cancer spread to other parts of their bodies.

Patients with oropharyngeal squamous cell carcinoma who had “matted” lymph nodes – nodes that are connected together – had a 69 percent survival rate over three years, compared to 94 percent for patients without matted nodes, according to a study published online ahead of print publication in Head & Neck. The oropharynx is an area that includes the back of the tongue, soft palate, throat and tonsils.

“The spread of cancer throughout the body accounts for about 45 percent of the deaths from oropharyngeal carcinoma,” says the study’s senior author, Douglas B. Chepeha, M.D., M.S.P.H., an associate professor of otolaryngology head and neck surgery at the U-M Medical School. “Our findings may help doctors identify patients who are at higher risk for having their cancer metastasize and who would benefit from additional systemic therapy. Conversely, some patients without matted nodes may benefit from a reduction of the current standard treatment, which would cut down on uncomfortable side effects.”

Notably, the findings indicate an increased risk independent of other established prognostic factors, such as the patient’s history of smoking or whether they have the Human papillomavirus (HPV), the study found. Smoking (tobacco and marijuana), heavy alcohol use and HPV infection have each been linked to the development of oropharyngeal squamous cell carcinoma.

Matted nodes appear to be an especially strong indicator of increased risk among patients who are HPV-positive, even though HPV-positive patients had better overall outcomes than their HPV-negative peers. The patients with the best outcomes were HPV-positive non-smokers.

“It’s not clear why we’re finding these survival differences for patients who have matted nodes,” says study lead author Matthew E. Spector, M.D., a head and neck surgery resident at U-M who won a national award from the American Head and Neck Society for this work. “It is possible that there are biological and molecular differences in these types of tumors, which can be explored in future research.”

The results affirm the value of having a team of doctors and researchers from different specialties – radiology, oncology, biostatistics and surgery – working together to find advances that can directly benefit patients, Chepeha says. “This was a collaborative effort and all of the authors made important contributions,” he adds.

The study tracked 78 cancer patients who were part of a clinical trial evaluating two cancer drugs in combination with intensity-modulated radiation therapy. All the patients had stage III or IV squamous cell carcinoma of the oropharynx and had not had any previous treatment. Sixteen of the 78 patients had matted nodes.

“It’s significant that we’ve identified this new marker that can help us predict which patients have worse survival odds,” Chepeha says. “Now we need to go one step further and figure out what mechanisms are at work and how we can use this knowledge to improve survival rates.”

Head and neck cancer statistics: An estimated 52,140 people will be diagnosed with head and neck cancer this year, and an estimated 11,460 people will die from the disease, according to the American Cancer Society.

Print Friendly
Spread The Word:
  • Digg
  • del.icio.us
  • Facebook
  • Google Bookmarks
  • email
  • Furl
  • MySpace
  • TwitThis
Continue reading...

200 Years of surgery: cutting to cure has come a long way

Sun, May 6, 2012

0 Comments

Source: abcnews.go.com
Author: Katie Moisse

The three-and-a-half-inch tumor in Cynthia Miller’s throat threatened to choke her, leaving her no choice but to have it removed.

“I had no idea I was even sick,” said Miller, 55, who lives in Maitland, Fla. “I woke up in the middle of the night coughing. … The next thing I knew they were booking emergency surgery.”

Instead of radical surgery — which would involved cutting her face, pulling teeth and breaking her jaw — Miller had her tumor removed through her mouth by a miniature robotic arm guided by the surgeon.

“With the robot, there are no cuts anywhere. No breathing tube, no broken bones,” said Dr. Bert O’Malley, who pioneered the procedure at the University of Pennsylvania’s Head and Neck Cancer Center in Philadelphia. “We go in through the mouth with a high-magnification 3-D camera and very small instruments, like a surgeon’s fingers but very tiny, and we’re able to remove the tumor without the side effects of traditional surgery.”

Side effects like spasms, difficulty with swallowing and speech, not to mention chronic pain.

“The more you disrupt and injure tissue, the greater the risk of dysfunction and chronic problems,” said O’Malley.

Today’s minimally invasive surgery is far different from the procedures of 200 years ago, when surgeons hacked through skin, muscle and bone briskly and brutally without anesthesia or antisepsis.

“Pain and the always-looming problem of infection restricted the extent of a surgeon’s reach,” Dr. Atul Gawande, a surgeon at Brigham and Women’s Hospital in Boston, wrote in a review published Wednesday in the New England Journal of Medicine’s 200th anniversary issue.

Even after the advent of anesthesia in 1846, surgeons continued to “choose slashing speed over precision,” Gawande wrote, describing a 19th century leg amputation in which the surgeon accidentally cut an assistant’s finger along with the patient’s limb.

“The patient and the assistant both died of sepsis, and a spectator reportedly died of shock, resulting in the only known procedure with a 300 percent mortality,” he wrote.

Unlike today’s surgeons dressed in sterile scrubs, masks, caps and booties, surgeons of yore wore black Prince Albert coats speckled with pus and dried blood from procedures past. It would take decades for them to recognize the importance of sterility.

Soon after, however, the arsenal of surgical procedures and their success rates quickly grew. From heart procedures to organ transplants to joint replacements, the “invasion of people’s bodies for cure” was becoming the norm, Gawande wrote.

American surgeons perform more than 50 million procedures a year, according to the review, meaning the average American can expect to undergo seven operations during his or her lifetime. Miller, who’s had four surgeries so far, said she’s amazed at how far the field has come.

“I went in on a Friday morning and came home on the Monday,” she said, recalling her surprisingly quick and painless recovery. “I’m thoroughly amazed. I’m in awe. Technology and man are coming together to enrich our world in ways that we could never have imagined.”

But being a pioneer in the field of surgery is not for the thin-skinned.

“The first time we presented this technique to head and neck community, most people stood up and said, ‘This is crazy. You don’t need this expensive technology. There are other surgical approaches.’ It never crossed our minds that the biggest barrier wouldn’t be the tumor, but others in our field,” O’Malley recalled. “But we kept going. And the more we did, the better we got. And it finally started gaining acceptance.”

Anesthesia, too, was once considered a fad that would fade with time.

“It takes creativity and a desire to change something for the better, not for the sake of innovation, to be a pioneer in surgery. But it takes organization and persistence to see it through,” said O’Malley. Indeed, surgery has come a long way, but it has room to improve. The risk of complications, while smaller than before, still looms.

“Just because you’re working through smaller holes doesn’t mean there’s no risk,” said O’Malley. “The risk is still there, just the side effects are smaller.”

If the 20th century brought minimally invasive procedures, the 21st may bring zero-invasive procedures.

“Scientists are already experimenting with techniques for combining noninvasive ways of seeing into the body through the manipulation of small-scale devices that can be injected or swallowed,” Gawande wrote.

He added that over time, surgery might even become fully automated. “A century into the future, a surgeon will tell the tale.”

Print Friendly
Spread The Word:
  • Digg
  • del.icio.us
  • Facebook
  • Google Bookmarks
  • email
  • Furl
  • MySpace
  • TwitThis
Continue reading...

Ireland: mouth cancer awareness day yields results

Sun, May 6, 2012

0 Comments

Source: http://www.dentistryiq.com/
Author: staff

Dentists are emphasizing the importance of early detection with mouth cancer, after 12 cases of the potentially deadly cancer were discovered on Mouth Cancer Awareness Day and one of these was discovered in Waterford.

The Irish Dental Association estimates that 10,000 people availed of free mouth cancer examinations carried out by participating dentists countrywide on September 21 of last year. As well as the confirmed cases, 286 people were advised to attend their GP for other related problems. Mouth Cancer Awareness Day was set up by a group of mouth, head and neck cancer survivors in September 2010. It is now a joint initiative by the Irish Dental Association, Irish Cancer Society, Dublin Dental University Hospital, Cork Dental University Hospital, the Dental Health Foundation and Mouth, Head and Neck Cancer Awareness Ireland.

The President of the IDA, Conor McAlister said the fact twelve cancers were discovered in one day showed the importance of early detection and the need for everyone to have a regular examination.

He said, “Three hundred cases of mouth cancer are detected here each year with 100 deaths and this type of cancer actually kills more Irish people than cervical cancer or skin melanoma.

“According to the National Cancer Register in Ireland, roughly 50% of all mouth cancers are diagnosed at an advanced stage. Hopefully the fact these 12 cases have been caught at an earlier stage means the impact on quality of life will be reduced.”

He added, “This year we saw up to 10,000 and I hope we can push on from that figure next year and keep the spotlight on this lethal form of the disease.”

Research shows that smoking and drinking alcohol are the main risk factors for mouth cancer and the risk is even greater if a person smokes and drinks. The most common symptoms are mouth ulcers that will not go away, swallowing difficulties and pain on the tongue and if people experience any of these, they are advised to visit their GP or dentist.

Print Friendly
Spread The Word:
  • Digg
  • del.icio.us
  • Facebook
  • Google Bookmarks
  • email
  • Furl
  • MySpace
  • TwitThis
Continue reading...

Ongoing surveillance needed to monitor trends in HPV rates after vaccination

Wed, May 2, 2012

0 Comments

Source: HemOnc Today

The ongoing monitoring of HPV-associated cancers via the National Program of Cancer Registries and the Surveillance, Epidemiology and End Results program indicate a decrease in the US rates for cervical cancer, yet disparities remain, according to data published in a recent Morbidity and Mortality Weekly Report.

Data pooled from the high-quality population-based cancer registry programs indicated that between 2004 and 2008, there were 12,080 HPV-associated cancers diagnosed annually among males and 21,290 among females.

Of the overall cases, cervical cancer was the most common diagnosis (11,967 annually), followed by oropharyngeal cancer (11,726 annually). Compared with whites and non-Hispanics, blacks and Hispanics had the highest rates for cervical and penile cancer. Conversely, vulvar cancer rates were highest among whites and non-Hispanics.

Anal cancer rates were highest among females (1.8 per 100,000) vs. males (1.2 per 100,000). Specifically, the rates were highest among white females and among black males.

HPV-associated cancer rates were highest among females in West Virginia (16.3 per 100,000) and among males in Washington, D.C. (11.6 per 100,000). Rates in the lowest tertile for HPV-associated cancers were most common in Maryland, Colorado and Utah, whereas rates in the highest tertile were found in Kentucky, Louisiana and Tennessee.

“The HPV vaccine will likely help decrease cervical cancer rates further and reduce the disparities,” the researchers wrote in the report. “Other HPV-associated cancers do not have approved screening programs; therefore, HPV vaccines are important prevention tools to reduce the incidence of non-cervical cancers.”

In an accompanying editorial, CDC officials wrote, “Reasons for variations in rates of noncervical HPV-associated cancers by race/ethnicity and state are not clear but might be attributable, in part, to demographics, screening practices, tobacco use or other factors related to HPV infection of persistence.”

This news story was resourced by the Oral Cancer Foundation, and vetted for appropriateness and accuracy.

Print Friendly
Spread The Word:
  • Digg
  • del.icio.us
  • Facebook
  • Google Bookmarks
  • email
  • Furl
  • MySpace
  • TwitThis
Continue reading...

Oncologists Favor Psychosocial Care, But Give It Short Shrift

Wed, May 2, 2012

0 Comments

Source: Oncology STAT

MIAMI (EGMN) – Oncologists endorse the idea of connecting cancer patients to psychosocial care at the conclusion of active treatment. But practice doesn’t align with beliefs, perhaps because they are unfamiliar with where to refer their patients for care.

Among 57 oncologists who responded to a survey in the southeastern United States, 35, or 61%, considered psychosocial care to be beneficial. A majority thought it was “important” following cancer treatment, reported Laurie Freeman-Gibb at the annual conference of the American Psychosocial Oncology Society (APOS).

But the oncologists said they spent just 4.2 minutes, on average, discussing psychosocial care during consultations, according to Ms. Freeman-Gibb, a lecturer in the department of nursing at the University of Windsor in Ontario, and her colleague Andrew Hatchett, Ph.D., of the University of Louisiana at Lafayette’s department of kinesiology.

And since only about 1 in 6 oncologists responded to the survey – it was sent to 350 practitioners – the findings may present an overly optimistic picture of what happens in real-life practice when a patient leaves active treatment and returns to the community for care.

“I think it’s sometimes a time constraint,” said Ms. Freeman-Gibb. “If you only have 20 minutes to see this person and you open the floodgates to what’s really going on, you might never get out the door … especially if you don’t know whom to tell the patient to call.”

Dr. Hatchett said the impetus for the study was a series of conversations he had with survivors, in which they seemed to indicate a “disconnect” in support after their active treatment ended. “It seemed as though after treatment the survivor was left to their own devices to acquire any additional help,” he said.

Many oncologists told the researchers that they would like to refer survivors for follow-up psychosocial care, but they don’t know what’s available, the investigators said.

No comprehensive registry exists that would outline the locations and qualifications of therapists, exercise and rehabilitation specialists, and support agencies that specialize in the psychosocial needs of cancer survivors. In Ireland, a national registry does just that, detailing not only the services available but also their cost, said Ms. Freeman-Gibb.

The organization that sponsored the meeting, APOS, offers a free helpline intended to connect cancer patients and survivors with community counseling services and other sources of support. However, the oncologists in the survey were unaware of that resource, the investigators noted.

Development of a “network of resources” remains a goal of the researchers, who plan to conduct an expanded online survey of a larger pool of oncologists to build on the findings of their pilot questionnaire.

Having a better sense of available resources might make oncologists more comfortable bringing up survivors’ psychosocial adjustment, added Ms. Freeman-Gibb: “Their attitude is great. They say they would love to refer patients. But they don’t.”

No outside funding was used to conduct the study.

This news story was resourced by the Oral Cancer Foundation, and vetted for appropriateness and accuracy.

Print Friendly
Spread The Word:
  • Digg
  • del.icio.us
  • Facebook
  • Google Bookmarks
  • email
  • Furl
  • MySpace
  • TwitThis
Continue reading...

Genes May Link Disparate Diseases

Wed, May 2, 2012

0 Comments

Source: The Wall Street Journal

Diseases that strike different parts of the body—and that don’t seem to resemble each other at all—may actually have a lot in common.

Scientists have identified the genetic basis for many separate diseases. Now, some researchers are looking at how the genes interact with each other. They are finding that a genetic abnormality behind one illness may also cause other, seemingly unrelated disorders. Sometimes diseases are tangentially linked, having just one gene in common. But the greater the number of shared genetic underpinnings a group of diseases has, the greater the likelihood a patient with one of the illnesses will contract another.

Researchers have found evidence, for example, that there is a close genetic relationship between Crohn’s disease, a gastrointestinal condition, and Type 2 diabetes, despite the fact the two conditions affect the body in very distinct ways. Other illnesses with apparently close genetic links are rheumatoid arthritis and Type 1 diabetes, the form of the disease that usually starts in childhood, says Joseph Loscalzo, chairman of the department of medicine at Brigham and Women’s Hospital in Boston.

This network approach, known among scientists as systems biology, could change the way medical specialists view and treat disease, according to some researchers. Rather than only looking to repair the parts of the body that are directly affected by illness, “we should be looking at what the wiring diagram [inside of cells] looks like,” says Albert-László Barabási, a physicist at Northeastern University’s Center for Complex Network Research in Boston.

Research work in the field is being done by geneticists, biologists and physicists at several universities and drug makers. The aim is to map how genes and the proteins they produce interact within cells in order to gain a better understanding of what goes wrong in the body to cause disease.

The information could help better predict a person’s risk of developing diseases, researchers say. It also could aid drug development. By figuring out which proteins are most critical to the normal functioning of the body, pharmaceutical companies could target those key proteins to treat disease. In some cases, drug companies may want to avoid interfering with key proteins to avoid too many unintended side effects, says Marc Vidal, director of the Center for Cancer Systems Biology at Dana-Farber Cancer Institute in Boston.

Since all the DNA in the human body was first sequenced in 2000, some 4,000 diseases with a known genetic basis have been identified, according to the National Institutes of Health. But only about 250 of those diseases have treatments, leaving many genetic puzzles left to untangle.

Scientists have long known that proteins and other molecules in the body don’t act alone. In order for the body to operate efficiently, biological substances must bind to or pass chemical messages to each other to start and stop working. The system is complex: Each gene is thought to produce, on average, five separate substances, mostly proteins, and these products interact with each other. When a protein, or group of proteins, malfunctions, it appears to give rise to a variety of distinct illnesses.

Dr. Barabási and his colleagues set out to see which diseases shared genetic underpinnings. They used information from a vast database at Johns Hopkins University in Baltimore that pulled together research from around the world on diseases and genes they were linked to. The scientists then mapped out a network indicating which diseases were seemingly connected to each other through common genes.

Of the 1,284 diseases mapped, nearly 900 had genetic links to at least one other disease. And 516 of these formed a so-called disease cluster, in which illnesses, mainly cancers, were linked to each other through multiple genetic connections.

Among the findings: Deafness shared at least one of 41 genes with over 20 other diseases, suggesting that it sits centrally in a cluster of other diseases. These include cardiomyopathy, a condition in which the heart muscle deteriorates; and ectodermal dysplasia, an abnormal development of the skin, hair, nails or teeth. Colon cancer shared at least one of 34 genes with 50 other diseases. Also in the cancer cluster were squamous cell carcinoma, a type of skin cancer, and throat cancer, but these had fewer genetic links between them. The work was published in the Proceedings of the National Academy of Sciences in 2007.

Because the diseases in the cluster were linked at the level of the cellular network, “the breakdown of one gene can lead to many apparently unrelated diseases,” says Dr. Barabási.

Another study by Dr. Barabási’s team aimed to see if their database analysis of genetically linked diseases was borne out in real life. The researchers analyzed more than 32 million Medicare hospital claims.

When patients developed multiple conditions, they were more likely to get illnesses that had close genetic links to their original disease than they were to get other disorders.

The study, published in 2009 in one of the journals of the Public Library of Science, PLoS Computational Biology, also showed that patients who developed diseases that tend to coincide with many others were more likely to die sooner than people whose diseases were more tangentially connected.

Using the data, the researchers estimated people’s likelihood of getting a second disease. A patient with ischemic heart disease, for example, has a 60% greater risk of getting Type 2 diabetes than an average healthy person.

Other biological processes also link seemingly unrelated diseases. In work published in 2008 in the Proceedings of the National Academy of Sciences, Dr. Barabási’s team identified a cluster of diseases, including diabetes and anemia, or coronary heart disease and hypertension, that appear to share common metabolic pathways, such as how chemicals are broken down or used in the body.

Dr. Vidal is currently working with Dr. Barabási and other researchers to map out all the possible protein interactions within a human cell. Dr. Vidal says about 20% of the project is finished, making it already the most complete map of the human protein network. The researchers also are developing protein-network maps for other organisms, including a yeast cell and Caenorhabditis elegans, a tiny worm with some 19,000 genes, about the same number as humans.

To test the role played by key proteins, or hubs, the researchers selectively deleted proteins or genes in the organisms and observed what happened. In the yeast cell, they found only about a quarter of the genes and proteins appeared to be essential, in that they connected to large numbers of other proteins and substances. The organism died when these hubs were removed, Dr. Vidal says.

This news story was resourced by the Oral Cancer Foundation, and vetted for appropriateness and accuracy.

Print Friendly
Spread The Word:
  • Digg
  • del.icio.us
  • Facebook
  • Google Bookmarks
  • email
  • Furl
  • MySpace
  • TwitThis
Continue reading...

$27 Million Verdict Against R.J. Reynolds for Cancer Victim

Tue, May 1, 2012

0 Comments

Source: JDsupra.com

A Florida man was awarded $27 million in compensatory and punitive damages against tobacco company R.J.

Reynolds last month after doctors told him that 44 years of smoking caused his lung cancer.

  • Plaintiff had lung removed due to cigarette addiction
  • Thousands of lawsuits pending against big tobacco companies
  • First payouts by big tobacco expected to be made today

Addictive Habits

Emmon Smith, a minister in Mariana, Florida, started smoking when he was a 13-year-old boy in 1944. Despite numerous attempts to quit, he couldn’t kick the addictive habit until he was forced to in 1992 by a cancer diagnosis and subsequent removal of one of his lungs.

Smith sued tobacco company R.J. Reynolds in 2008, and in March of this year a jury awarded him $10 million in compensatory damages and $20 million in punitive damages; however, they found the plaintiff 30 percent at fault so he will receive only $7 million of the compensatory award, for a total of $27 million.

Smith’s suit was led by attorney Richard Diaz  as well as a team of attorneys from Crabtree & Associates and Ratzan Law Group.

The Smith case was just one of more than 8,000 lawsuits against tobacco companies stemming from a 1990s class action known as the Engle case. In 2000, a Florida jury awarded class members a stunning $145 billion in punitive damages, finding that cigarettes are dangerous, addictive, carcinogenic, and most importantly, that tobacco companies knew all this and lied about it. “They found that tobacco was a defective product, that the companies were negligent, guilty of fraud, caused various diseases including lung cancer, were involved in conspiracy to defraud the American people and on and on,” says Stuart Ratzan of the Ratzan Law Group.

Justice at Last

Among the diseases found to be caused by smoking were aortic aneurysm, bladder cancer, cerebral vascular disease, cervical cancer, chronic obstructive pulmonary disease, coronary heart disease, esophageal cancer, kidney cancer, laryngeal cancer, lung cancer, complications of pregnancy, oral cavity/tongue cancer, pancreatic cancer, peripheral vascular disease, pharyngeal cancer and stomach cancer.

However, the Florida Supreme Court overturned the $145 billion punitive part of the Engle award in 2006. “The Supreme Court ruled that individual plaintiffs would have to file suit for damages individually,” Ratzan explains. “Punitive damages had to be reversed and each member of the class had to file a case to prove how much damages they were entitled to.”

Today thousands of suits are still pending. “Plaintiffs have to prove they were addicted to cigarettes, that cigarettes caused them lung cancer, or pulmonary disease, or one of the other diseases,” says Ratzan.

Earlier this month the United States Supreme Court declined to hear an appeal filed by R.J. Reynolds over a $28.3 million award, and today the company is expected to finally pay out the damages it owes in the first two Engle progeny cases, with thousands left to go. “Maybe one day the class will get its justice,” Ratzan says.

Print Friendly
Spread The Word:
  • Digg
  • del.icio.us
  • Facebook
  • Google Bookmarks
  • email
  • Furl
  • MySpace
  • TwitThis
Continue reading...

Robotic Surgery Is Useful Option for Oral Cancer

Mon, Apr 30, 2012

0 Comments

Source: Onclive.com

transoral robotic surgeryMinimally invasive transoral robotic surgery (TORS), used alone or combined with adjuvant therapy, provides good functional and oncologic outcomes in patients with oropharyngeal squamous cell carcinoma (OPSCC), new research suggests.

The results were especially impressive in patients with human papillomavirus (HPV) infection, which is currently the most common cause of OPSCC in Europe and the United States.

Eric J. Moore, MD, associate professor of Otolaryngology at the Mayo Clinic in Rochester, Minnesota, and coauthors reviewed a prospective database of patients with previously untreated OPSCC arising in the tonsil or base of the tongue who underwent TORS at their institution during a recent 2-year period.

In 2011, about 12,000 individuals in the United States were diagnosed with OPSCC, according to the authors. The most common sites are the tonsillar fossa and base of the tongue. Customarily, OPSCC has been treated with combined modality therapy, including open surgical resection through mandibulotomy, neck dissection, and adjuvant radiation therapy or combined chemotherapy and radiation therapy. TORS was later introduced to improve access to these tumors.

Functional outcomes of the study included gastrostomy tube dependence and tracheostomy dependence. Oncologic outcomes included local, regional, and distant control and disease-specific and recurrence-free survival.

Overall, 66 patients who underwent TORS as their primary treatment were followed for a minimum of 2 years. Sixty-four patients, or 97%, were able to tolerate an oral diet and maintain their nutritional needs before initiating adjuvant therapy at 4 weeks. Only 3 patients, or 4.5%, required long-term gastrostomy tube use, and one (1.5%) had long-term tracheotomy.

Three-year recurrence-free survival was achieved in 92.4% of patients, and 95.5% were alive and disease-free at the latest assessment.

Importantly, the analysis also demonstrated a strong correlation between disease control and HPV status. The 3-year survival rate was 92% in protein 16 assay (p16)-positive patients versus 52% in p16-negative patients. Most patients in the study had HPV-associated OPSCC.

The authors cited numerous advantages of TORS as primary therapy in OPSCC, including “the ability to stage the tumor adequately, to eradicate the primary tumor and the involved lymph nodes reliably and completely in a single setting, and to add adjuvant therapy in a rational and individually designed manner.” In addition, the ability to preserve normal tissue and neurovascular supply helps patients heal faster and recover oropharyngeal function.

“The authors cited numerous advantages of TORS as primary therapy in OPSCC.”

The authors said that the major study limitation was the lack of an alternative treatment group for comparative analysis. Selection bias represented an additional drawback, given that patients with higher T-stage tumors that cannot be exposed or resected using a transoral approach were ineligible for the study.

This news story was resourced by the Oral Cancer Foundation, and vetted for appropriateness and accuracy.

Print Friendly
Spread The Word:
  • Digg
  • del.icio.us
  • Facebook
  • Google Bookmarks
  • email
  • Furl
  • MySpace
  • TwitThis
Continue reading...
Older Entries Newer Entries